Bureaucracy stops French patients accessing innovative treatmentLe Monde Idées (p.7) published a piece on Monday in which doctors deplored that the French healthcare system “no longer assures patients rapid and fair access to the most innovative drugs”.
'Four areas to watch out for' after social security funding billLiberation wrote an article on Tuesday (p.19) listing the four medicines-related areas to watch out for this autumn following the social security funding bill (PLFSS).
Patient petition launched against trade secrets in Merck & Co’s Levothyrox affairAn association of patients with thyroid illnesses has launched a petition denouncing France’s drug regulator ANSM for its role in the affair surrounding Merck’s Levothyrox, reported Le Monde on Monday (p.8). The petition is addressed to France’s health minister Agnès Buzyn.
Unjustifiable drug prices profit shareholdersThree professors said the pharma industry is one of the most profitable for shareholders in Le Monde Idées (p.7) on Monday. They mentioned the progress made in creating new targeted innovative therapies to treat cancer and the “exorbitant prices” that went with them.
Figures published on savings to be made in social security funding billLe Figaro reported on Wednesday (p.22) that the French finance ministry has published the economic, social and finance report detailing where the €3.8 billion of savings to be made in 2019 are going to come from (APMHE 59977).
Community care spend needs managing, says national audit officeFrance’s national audit office is wary about the community care spend, Le Figaro reports on Friday (p.22).
Leo Pharma’s Kyntheum reimbursed in FranceLeo’s Kyntheum for psoriasis has been approved in France, and the company has a drug for eczema in the pipeline (APMHE 59965).
Nobel medicine prize award for immunology researchLiberation (p.15) in a brief on Tuesday announced that two researchers, Tasuku Honjo from Japan and James Allison from the U.S., have been awarded the Nobel prize for Medicine for their research in immunology, which is now in vogue in the field of cancerology.
Pfizer head steps downLe Figaro reported in a brief on Tuesday (p.26) that Pfizer CEO Ian Read would step down after eight years. Chief operating office Dr Albert Bourla is set to take over in 2019.
Sanofi has cancer treatment approved by FDA for first time in six yearsLes Echos reported on Tuesday (p.21) that Sanofi had a cancer treatment, Libtayo (cemiplimab), approved by the U.S. Food and Drug Administration for the first time in six years.
Diabetes drug may help depressionThe free daily newspaper 20 minutes reported in a brief on Wednesday (p.7) that French scientists have discovered that AdipoRon, a diabetes drug, may play a role in treating depression.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.